Kate Barrientos
About Kate Barrientos
Kate Barrientos is the Translational Pathology Research Lead at Bristol-Myers Squibb in New Jersey, United States.
Company
Kate Barrientos is currently working at Bristol-Myers Squibb in New Jersey, United States. Her role as Translational Pathology Research Lead involves leading projects in translational pathology, focusing on the application of advanced technologies such as multiplex IHC, digital pathology, digital spatial profiling, and single-cell RNA-Seq. The company is known for its contributions to biopharmaceutical development, particularly in the field of oncology.
Title
As a Translational Pathology Research Lead, Kate Barrientos leads various projects aimed at enhancing the utility and scalability of innovative technologies. She collaborates with different academic thought leaders and manages a matrix of functional groups including biomarker and translational medicine leads, technical subject matter experts, bioinformatics teams, and discovery and clinical teams.
Education and Expertise
Kate Barrientos holds a Doctor of Philosophy degree from Duke University, where she studied from 2003 to 2008, focusing on Biology, Pharmacology, and Toxicology. She also earned a Bachelor of Science degree in Biology and Psychology from Penn State University, where she studied from 1999 to 2003. Her education has equipped her with extensive knowledge in biological sciences and pharmacology.
Background
Kate Barrientos has a diverse background in the field of biological sciences and pharmacology. Prior to her current role, she served as the CMC Analytical Team Lead at Bristol-Myers Squibb from 2015 to 2018 in New Jersey. She also worked at GSK in Hayes, Hillingdon, United Kingdom, first as a Postdoctoral Associate (2009-2011) and then as an Investigator (2011-2015). Her early career included positions at Duke University as a Doctoral Graduate Student and at Penn State University as an Undergraduate Laboratory Assistant.
Achievements
In her current role at Bristol-Myers Squibb, Kate Barrientos leads translational projects that incorporate cutting-edge technologies such as multiplex IHC, digital pathology, digital spatial profiling, and single-cell RNA-Seq. She also collaborates with academic thought leaders through the BMS International Immuno-Oncology Network (II-ON). Additionally, she acts as a matrix lead, coordinating efforts across functional groups, thereby contributing to the advancement of translational medicine and oncology research.